

**In the Claims**

This listing of the claims will replace all prior versions and listings of claims in the application:

1.-67. (Canceled)

68. (New) A method of improving myocardial function of a subject in need of such treatment, the method comprising administering an antibody that binds to an epitope of Endothelial Monocyte Activating Polypeptide II (EMAP II), wherein the epitope consists of the amino acid sequence of SEQ ID NO:6, in an amount sufficient to inhibit the anti-angiogenic activity of EMAP II in the subject, thereby improving myocardial function in the subject.

69. (New) The method of claim 68, wherein the subject is afflicted with myocardial ischemia.

70. (New) The method of claim 68, wherein the antibody is a polyclonal, monoclonal or humanized antibody.

71. (New) A method of improving myocardial function of a human subject in need of such treatment, the method comprising administering an antibody that binds to an epitope of Endothelial Monocyte Activating Polypeptide II (EMAP II), wherein the epitope consists of the amino acid sequence of SEQ ID NO:6, in an amount sufficient to inhibit the anti-angiogenic activity of EMAP II in the subject, thereby improving myocardial function in the subject.

72. (New) The method of claim 71, wherein the human subject is afflicted with myocardial ischemia.

73. (New) The method of claim 71, wherein the antibody is a polyclonal, monoclonal or humanized antibody.